Abstract
Age is one of the most important prognostic factors in glioblastoma patients, but no standard treatment has been established for elderly patients with this condition. We therefore conducted a retrospective cohort study to evaluate treatment regimens and outcomes in elderly glioblastoma patients. The study population consisted of 79 glioblastoma patients aged ≥76 years (median age 78.0 years; 34 men and 45 women). The median preoperative Karnofsky performance status (KPS) score was 60. Surgical procedures were classified as biopsy (31 patients, 39.2 %), <95 % resection of the tumor (21 patients, 26.9 %), and ≥95 % resection of the tumor (26 patients, 33.3 %). Sixty-seven patients (81.0 %) received radiotherapy and 45 patients (57.0 %) received chemotherapy. The median overall progression-free survival time was 6.8 months, and the median overall survival time was 9.8 months. Patients aged ≥78 years were significantly less likely to receive radiotherapy (p = 0.004). Patients with a postoperative KPS score of ≥60 were significantly more likely to receive maintenance chemotherapy (p = 0.008). Multivariate analyses identified two independent prognostic factors: postoperative KPS score ≥60 (hazard ratio [HR] = 0.531, 95 % confidence interval [CI] 0.315–0.894, p = 0.017) and temozolomide therapy (HR = 0.442, 95 % CI 0.25–0.784, p < 0.001).The findings of this study suggest that postoperative KPS score is an important prognostic factor for glioblastoma patients aged ≥76 years, and that these patients may benefit from temozolomide therapy.
Similar content being viewed by others
References
Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ Jr, Mehta MP (2011) Validation and simplification of the radiation therapy oncology group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623–630
Stupp R, Mason WP, Van den Bent MJ, European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, Gardiman M, Scienza R, Monfardini S, Silvio M, Ermani M (2003) A prospective study on glioblastoma in the elderly. Cancer 97:657–662
Gállego Pérez-Larraya J, Ducray F, Chinot O et al (2011) Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 29:3050–3055
Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, van den Bent MJ (2012) Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 39(4):350–357
Gulati S, Jakola AS, Johannesen TB, Solheim O (2012) Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg 78:518–526
Committee of Brain Tumor Registry of Japan (2009) Report of brain tumor registry of Japan (1984–2000), 12th edition. Neurol Med Chir (Tokyo) 49(Suppl):S1–S96
Piccirilli M, Bistazzoni S, Gagliardi FM, Landi A, Santoro A, Giangaspero F, Salvati M (2006) Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori 92:98–103
Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Kita D, Ciernik IF, Vaccarella S, Franceschi S, Kleihues P, Lütolf UM, Ohgaki H (2009) Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology 33:17–22
Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108:642–648
Scott JG, Suh JH, Elson P et al (2011) Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 13:428–436
Balducci M, Fiorentino A, De Bonis P et al (2012) Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol 29:3478–3483
Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, Schulz-Ertner D (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70:987–992
Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M (2011) Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol 103:611–618
Fiorica F, Berretta M, Colosimo C et al (2010) Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 51:31–35
Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, Rödel C (2010) Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 97:382–386
Kushnir I, Tzuk-Shina T (2011) Efficacy of treatment for glioblastoma multiforme in elderly patients (65+): a retrospective analysis. Isr Med Assoc J 13:290–294
Oszvald A, Güresir E, Setzer M, Vatter H, Senft C, Seifert V, Franz K (2012) Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 116:357–364
Stummer W, Nestler U, Stockhammer F et al (2011) Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 103:361–370
Minniti G, De Sanctis V, Muni R et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97–103
Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH, Iwamoto FM (2012) Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol 109:391–397
Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 114:587–594
Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH (1998) Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 42:981–987
Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, Brem H, Quiñones-Hinojosa A (2011) Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 18:239–245
Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214
Fiorica F, Berretta M, Colosimo C et al (2010) Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 51:31–35
Gállego Pérez-Larraya J, Ducray F, Chinot O et al (2011) Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 29:3050–3055
Hashem SA, Salem A, Al-Rashdan A et al (2012) Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme. J Med Imaging Radiat Oncol 56:204–210
Malmström A, Grønberg BH, Marosi C, Nordic Clinical Brain Tumour Study Group (NCBTSG) et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926
Wick W, Platten M, Meisner C, NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715
Acknowledgments
We are grateful to Dr. Haruyasu Fujita, Department of Socio-Environmental Medicine, Public Health Division, Gunma University Graduate School of Medicine, Gunma, Japan, for his advice on the statistical analyses.
Conflict of interest
There are no conflicts of interest to declare.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Uzuka, T., Asano, K., Sasajima, T. et al. Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study. J Neurooncol 116, 299–306 (2014). https://doi.org/10.1007/s11060-013-1291-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-013-1291-3